Citations

Clear

643 citation(s) found for "Go, Lucas T".

Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
Grever, Michael R. , Lucas, David , Dewald, Gordon W., Reed, John C. , Kitada, Shinichi, Flinn, Ian W. , Tallman, Martin S. , Appelbaum, Frederick R. , Larson, Richard A. , Paietta, Elisabeth , Jelinek, Diane F., Byrd, John C. , Byrd, John C. , Neuberg, Donna , Gribben, John G. , Larson, Richard A , Flinn, Ian W , Byrd, John C

Mayo Clinic

Journal of Clinical Oncology | February 5, 2007 | Volume: 25 | Issue: 7 | Pages: 799-804

10.1200/jco.2006.08.3089 | PMID 17283363 Get It

Purpose Genomic features including unmutated immunoglobulin variable region heavy chain (IgV H ) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome. Patients and Methods We prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival (PFS) using samples and data from 235 patients enrolled onto a therapeutic trial. Patients received either fludarabine (FL; n = 113) or fludarabine plus cyclophosphamide (FC; n = 122) as part of a US Intergroup randomized trial for previously untreated CLL patients. Results Complete response (CR) rates were 24.6% for patients receiving FC and 5.3% for patients receiving FL (P = .00004). PFS was statistically significantly longer in patients receiving FC (median, 33.5 months for patients receiving FC and 19.9 months for patients receiving FL; P < .0001). The occurrence of del(17p13.1) (hazard ratio, 3.428; P = .0002) or del(11q22.3) (hazard ratio, 1.904; P = .006) was associated with reduced PFS. CR and overall response rates were not significantly different based on cytogenetics, IgV H mutational status, CD38 expression, or p53 mutational status. Expression of ZAP-70, Bcl-2, Bax, Mcl-1, XIAP, Caspase-3, and Traf-1 was not associated with either clinical response or PFS. Conclusion These results support the use of interphase cytogenetic analysis, but not IgV H , CD38 expression, or ZAP-70 status, to predict outcome of FL-based chemotherapy. Patients with high-risk cytogenetic features should be considered for alternative therapies.
μ-,δ- AND κ-RECEPTOR AGONISTS PRESERVE THE ADRENAL MEDULLARY RESPONSE EVOKED BY SEVERE HEMORRHAGE
Gaumann, Dorothee M., Yaksh, T. L., Tyce, G. M., Lucas, Darlene L.

Mayo Clinic

Anesthesiology | October 10, 2006 | Volume: 67 | Issue: 3 | Pages: A677-A677

10.1097/00000542-198709001-00677 Get It

Radium-226, Radium-228, Lead-210, and Fluorine in Persons With Osteogenic Sarcoma
Lucas, H. F., Holtzman, R.B., Dahlin, David C., Lucas, H. F.

Mayo Clinic

Science | October 5, 2006 | Volume: 144 | Issue: 3626 | Pages: 1573-1575

10.1126/science.144.3626.1573 | PMID 14169342 Get It

Concentrations of the naturally occurring alpha-emitting radioelements, radium-226, radium-228, and lead-210, and of stable lead and fluorine were determined in bone specimens from 32 individuals having a verified osteogenic sarcoma. Comparison of these results with those for the average person showed no significant differences in either the absorbed dose (rad) from the accumulated radioisotopes or in the concentrations of the elements studied.
IC–P–087: Annualized decrease in plasma Aβ42 correlates with annualized decrease in hippocampal volume
Graff‐Radford, Neill R. , Weigand, Stephen D. , Shuing, Maria M., Lucas, John A. , Younkin, Linda H., Petersen, Ronald C. , Younkin, Steven G. , Knopman, David S. , Boeve, Bradley F. , Crook, Julia E. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_22 | Pages: No page available

10.1016/j.jalz.2006.05.2292 Get It

P4–159: Neuropathology of mild cognitive impairment evolving into clinically probable dementia with Lewy bodies
Parisi, Joseph E., Graff‐Radford, Neill R. , Lucas, John A. , Ivnik, Robert J., Petersen, Ronald C. , Boeve, Bradley F. , Ferman, Tanis J. , Smith, Glenn E. , Dickson, Dennis W. , Knopman, David S. , Geda, Yonas E.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_18 | Pages: No page available

10.1016/j.jalz.2006.05.1898 Get It

P3–102: Annualized decrease in plasma Aβ42 correlates with annualized decrease in hippocampal volume
Graff‐Radford, Neill R. , Weigand, Stephen D. , Shuing, Maria M., Lucas, John A. , Younkin, Linda H., Petersen, Ronald C. , Younkin, Steven G. , Knopman, David S. , Boeve, Bradley F. , Crook, Julia E. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_13 | Pages: No page available

10.1016/j.jalz.2006.05.1370 Get It

A Brief Report on WAIS-R Normative Data Collection in Mayo's Older African Americans Normative Studies
Lucas, John A. , Ivnik, Robert J., Smith, Glenn E. , Ferman, Tanis J. , Willis, Floyd B. , Petersen, Ronald C. , Graff‐Radford, Neill R., Ferman, Tanis J

Mayo Clinic

The Clinical Neuropsychologist | January 3, 2006 | Volume: 19 | Issue: 2 | Pages: 184-188

10.1080/13854040590945283 | PMID 16019703 Get It

Mayo's Older African Americans Normative Studies: Normative Data for Commonly Used Clinical Neuropsychological Measures
Lucas, John A. , Ivnik, Robert J., Willis, Floyd B. , Ferman, Tanis J. , Smith, Glenn E. , Parfitt, Francine, Petersen, Ronald C. , Graff‐Radford, Neill R. , Ferman, Tanis J

Mayo Clinic

The Clinical Neuropsychologist | January 3, 2006 | Volume: 19 | Issue: 2 | Pages: 162-183

10.1080/13854040590945265 | PMID 16019702 Get It

[O2‐02‐06]: Using family history to enrich recruitment in prevention trials: Does relative's age matter?
Sano, Mary , Bell, Karen L. , Andrews, Howard , Tsai, Wei‐Yann , Lucas, John A. , Graff‐Radford, Neill R. , Bolla, Karen I., Rabins, Peter V., Jacobs, Diane M.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.339 Get It

[P‐011]: Plasma AB levels as a premorbid biomarker for cognitive decline, mild cognitive impairment (MCI) and Alzheimer disease (AD)
Graff‐Radford, Neill R. , Lucas, John A. , Ivnik, Robert J., Younkin, Linda H., Petersen, Ronald C. , Younkin, Steven G. , Crook, Julia E. , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_1 | Pages: No page available

10.1016/j.jalz.2005.06.073 Get It